Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Rich and sparse bevacizumab serum concentrations were collected from Phase I through IV studies in early and metastatic cancers. Bevacizumab was given intravenously as single agent or in combination with chemotherapy for single- and multiple-dose schedules.
Model-building used 8943 bevacizumab concentrations from 1792 patients with colon/colorectal, non-small cell lung, kidney, pancreatic, breast, prostate and brain cancer. Bevacizumab doses ranged from 1 to 20 mg/kg given once every 1, 2 or 3 weeks. A two-compartment model best described the data. The population estimates of clearance (CL), central volume of distribution (V1) and half-life for a typical 70-kg patient were 9.01 mL/h, 2.88 L and 19.6 days. CL and V1 increased with body weight and were higher in males than females by 14 and 18 %, respectively. CL decreased with increasing albumin and decreasing alkaline phosphatase. The final model was externally validated using 1670 concentrations from 146 Japanese patients that were not used for model-building. Mean prediction errors were -2.1, 3.1 and 1.0 % for concentrations, CL and V1, respectively, confirming adequate predictive performance.
A robust bevacizumab pharmacokinetic model was developed and externally validated, which may be used to simulate bevacizumab exposure to optimize dosing strategies. Asian and non-Asian patients exhibited similar bevacizumab pharmacokinetics. Given the similarity in pharmacokinetics among monoclonal antibodies, this may inform pharmacokinetic studies in different ethnic groups for other therapeutic antibodies.
Cancer chemotherapy and pharmacology. 2016 Jun 21 [Epub ahead of print]
Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie H Gosselin, Sandhya Girish, David E Allison, Jin Jin
Clinical Pharmacology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA. ., Pharsight Consulting Services, Montreal, QC, Canada., Pharsight Consulting Services, Marseille, France., Clinical Pharmacology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA., Pharsight Consulting Services, Montreal, QC, Canada., Clinical Pharmacology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA., Clinical Pharmacology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA., Clinical Pharmacology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA. .